

# **IOPtima, one of BioLight's subsidiaries, is expanding its commercial operations in Asia: signed a distribution agreement for the sale of six glaucoma surgery systems in Taiwan.**

**IOPtima has regulatory approvals to market the system in Europe, Mexico and Israel and is in the process to obtain regulatory approval in China in the coming months.**

## **Ronen Castro, CEO of IOPtima:**

**"The signing of the agreement with a leading distributor in the Ophthalmology field in Taiwan is part of our marketing plan that includes introducing the IOPtimate™ system to additional markets within Asia and raising awareness among glaucoma specialists for its clinical benefits of the product for the promotion of commercial activity. We hope to start operating in China soon."**

Tel Aviv, Israel, December 31, 2013: BioLight Israeli Life Sciences Investments Ltd. (TASE: BOLT), which implements a unique strategy for encouraging innovation in the field of life sciences, through the creation of clusters of companies around a defined medical condition, announced today that its subsidiary, IOPtima (87.17%), has signed an exclusive distribution agreement with a leading distributor in the field of Ophthalmology in Taiwan in which the distributor will purchase at least 6 IOPtimate™ systems for performing a unique surgery to treat glaucoma. IOPtima estimates that revenues from sales during the first period in accordance with this distribution agreement will be about 1.5 million NIS. As part of the distribution agreement, the distributor shall the costs for product registration and reimbursement for the IOPtimate™ unique medical procedure performed using the product. In addition, the distributor will bear costs related to marketing, sales and advertising of the product in Taiwan, and will install the products for customers, perform training and provide post-sale service.

The IOPtimate™ system, which was developed by IOPtima, which is included among BioLight's ophthalmic cluster, is based on CO2 laser technology that allows the performance of surgery for treating Glaucoma without penetrating the internal part of the eye.

The distributor in Taiwan is a leading distributor in the Ophthalmology field in that country, representing a number of leading international companies in the ophthalmic field and has vast experience in the glaucoma disease. The agreement is for a period of three years, commencing at the time the regulatory approval in Taiwan will be received, with an option for renewal for additional three year if the distributor will meet minimum purchase quantities as stated in the agreement. Expected time until regulatory approval is obtained from the Ministry of Health in Taiwan is one year.

As part of IOPtima operations in large markets, led by the Asian markets, the company has recently installed a system in the central hospital for eyes in Hong-Kong, Hong Kong Eye Hospital. In February 2014 IOPtima planes to present at the ICGS (the International Conference for Glaucoma) in Singapore and in March 2014, to present at the COOC (Chinese Ophthalmic annual conference) in Shanghai.

**Ronen Castro, CEO of IOptima:** "We are working to establish significant operations in the Asian markets and this agreement with a leading distributor in the ophthalmic field in Taiwan is another milestone in our marketing plan. The glaucoma in Taiwan is based mostly on medications that their effectiveness is limited, and as such, this market begins to open up to new surgical techniques and is expected to grow significantly in the coming years. Furthermore, this agreement is part of the expansion of our operations in Asia, including the installation of our system in the central hospital in Hong-Kong, presentation at international conferences in China and Singapore, and anticipation to the regulatory approval in China in the coming months. We believe the Chinese market in particular has a significant market potential and will hopefully begin to operate in it very soon."

IOptima has regulatory approvals to market the IOptimate™ system in Europe, Mexico and Israel, is in the process to obtain regulatory approval in China in the coming months and preparing for discussions regarding the regulatory pathway in the U.S.

**Glaucoma:**

Glaucoma, which created pressure within the eye causes damage to the optic nerve that may lead to full or partial blindness, is considered the second most common cause of blindness worldwide. According to estimates commonly accepted in the field, there are now about 67 million people worldwide that suffer from the disease. Glaucoma is usually a chronic disease requiring lifelong treatment, and based on assessments, the global market for drug therapy and surgery, is estimated at \$ 5 billion annually.

**About BioLight:**

BioLight operates to invest, manage and promote unique solutions, which aim to address the real unmet needs that exists in the areas of cancer diagnostics and in the fields of glaucoma and dry eye. The company implements an investment and management model which aimed to create unique synergies between the clusters' companies to allow different angles of looking at the field, expanding exposure to new ideas and approaches, exploiting economies of scale, reducing time to market and increase value to investors.

Today BioLight is operating in two main areas of activity: cancer diagnostics, through MICROMEDIC (TASE: MCTC), which BioLight holds - 29.06% of the issued and outstanding, and in the glaucoma and dry eye diseases, through XLVision, a private company wholly owned by BioLight.

For further information, please visit: [www.bio-light.co.il](http://www.bio-light.co.il)